Challenge
The key uncertainty was whether existing pivotal evidence could support registration in the EU and UK.
A client’s pivotal data package had been generated outside the EU and UK, leaving an open question about its acceptability for registration in those markets. The client’s initial preference was to request centralised scientific advice from the European Medicines Agency (EMA).
Solution
The team defined the question the client needed answered before choosing the advice pathway. This kept the interactions focused on data acceptability.
Reframe the regulatory question
The team assessed what needed to be established about the foreign-generated data before committing to centralised scientific advice.
Compare EU and UK perspectives
Parallel national interactions with an EU reference state and the MHRA explored their views on the same pivotal data package.
Inform the submission strategy
The interactions explored any differences in expectations before the client committed to a filing strategy based on its existing evidence.
Results
Regulatory strategy clarified
The advice clarified the regulatory position on the data package and supported an informed submission strategy. The engagement also strengthened the client team’s ability to assess future foreign-data cases.
